<SEC-DOCUMENT>0001144204-19-033391.txt : 20190701
<SEC-HEADER>0001144204-19-033391.hdr.sgml : 20190701
<ACCEPTANCE-DATETIME>20190701162337
ACCESSION NUMBER:		0001144204-19-033391
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190626
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190701
DATE AS OF CHANGE:		20190701

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVAVAX INC
		CENTRAL INDEX KEY:			0001000694
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222816046
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26770
		FILM NUMBER:		19933485

	BUSINESS ADDRESS:	
		STREET 1:		20 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-268-2000

	MAIL ADDRESS:	
		STREET 1:		20 FIRSTFIELD ROAD
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv524622_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C.&nbsp;20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION&nbsp;13 OR 15(d)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): June 26, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVAVAX, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>000-26770</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>22-2816046</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or Other Jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of Incorporation)</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>20 Firstfield Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Gaithersburg, Maryland 20878</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of Principal Executive Offices,
including Zip Code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(240) 268-2000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Former name or former
address, if changed since last report.) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Title of each class</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common Stock, Par Value $0.01 per share</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">NVAX</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Nasdaq Global Select Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: 0.75in; color: #211D1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-indent: -3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #211D1E">Emerging
growth company&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #211D1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #211D1E">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>Item 1.01. Entry into a Material Definitive
Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 26, 2019, Novavax, Inc.
(the &ldquo;Company&rdquo;) entered into an asset purchase agreement (the &ldquo;Agreement&rdquo;) with Paragon Bioservices,
Inc., a unit of Catalent Biologics (&ldquo;Paragon&rdquo;), pursuant to which the Company agreed to sell to Paragon certain
assets related to the Company&rsquo;s biomanufacturing and development activities located at the facilities situated at each
of 20 Firstfield Road in Gaithersburg, Maryland 20878 and 9920 Belward Campus Drive in Rockville, Maryland 20850, for a
purchase price of (i) $18.0 million, including $1.5 million to be held in escrow for one year following the closing of
the transaction, plus (ii) an additional fee to purchase laboratory supplies of approximately $0.4 million, subject to
certain adjustments. The Company and Paragon also agreed to enter into other ancillary agreements upon the closing of
the transactions contemplated by the Agreement, including, among others, a Transition Services Agreement obligating the
Company and certain of its affiliates to provide certain transition services to Paragon and certain of its affiliates for a
limited period of time following closing of the transaction, a Non-Commercial GMP Manufacturing Services Agreement pursuant
to which Paragon will provide to the Company certain services as set forth therein, including process and analytical
development services at preferred client pricing and an Interim Services Agreement pursuant to which Paragon will provide to
the Company certain services as set forth therein, including process and analytical development and manufacturing services at
time and materials pricing. Subject to the satisfaction of customary closing conditions set forth in the Agreement, the
Company expects the transaction to close in July 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing is a summary of certain of
the provisions of the Agreement and is qualified in its entirety by reference to the full text thereof, which will be filed as
an exhibit in a subsequent periodic report of the Company. Readers should review the Agreement for a more complete understanding
of the terms and conditions associated with the transaction. The Agreement will be filed to provide investors and securities holders
with information regarding its terms. It is not intended to provide any other factual information about the parties to the Agreement
or the assets to be sold. The Agreement contains representations and warranties that the parties to the Agreement made solely for
the benefit of each other. The assertions embodied in such representations and warranties are qualified by information contained
in confidential disclosure schedules that the parties exchanged in connection with signing the Agreement. In addition, these representations
and warranties (i) may be intended not as statements of fact, but rather as a way of allocating risk to one of the parties if those
statements prove to be inaccurate, (ii) may apply materiality standards different from what may be viewed as material to investors
and securities holders, and (iii) were made only as of the date of the Agreement or as of such other date or dates as may be specified
in the Agreement. Moreover, information concerning the subject matter of such representations and warranties may change after the
date of the Agreement, which subsequent information may or may not be fully reflected in the Company&rsquo;s public disclosures.
Investors and securities holders are urged not to rely on such representations and warranties as characterizations of the actual
state of facts or circumstances at this time or any other time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01. Regulation FD Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 27, 2019, the Company and Paragon
issued a joint press release, a copy of which is filed as Exhibit 99.1 hereto and incorporated herein by reference, announcing
the execution of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is furnishing the information
contained in this Item 7.01 of this report and Exhibit 99.1 to this report pursuant to Item 7.01 of Form 8-K promulgated by the
SEC. This information shall not be deemed to be &ldquo;filed&rdquo; with the SEC for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that section, nor
shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such filing. By filing this current report on Form 8-K and furnishing
this information, the Company makes no admission as to the materiality of any information contained in this Item 7.01 of this report
and in Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Exhibit&nbsp;No.</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1pt solid; vertical-align: top"><FONT STYLE="font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 88%; font-size: 10pt; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="tv524622_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="tv524622_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Joint
    Press Release of Novavax, Inc. and Paragon Bioservices, Inc. issued June 27, 2019 (furnished herewith).</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOVAVAX, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="width: 45%; padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John A. Herrmann III</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John A. Herrmann III</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 3pt; padding-left: 3pt">&nbsp;</TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Vice President, General Counsel and Corporate Secretary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: July 1, 2019</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv524622_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white"><B>Novavax
and Catalent Biologics Enter Strategic Partnership:</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white"><B>Allowing
Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax&rsquo; Manufacturing Assets and Capabilities</B></FONT></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Manufacturing equipment and related assets to be sold to Catalent&rsquo;s
Paragon Gene Therapy for $18 million in cash</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Over 100 manufacturing and quality employees to join Catalent</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Paragon Gene Therapy to take over two clinical development and
manufacturing sites in Gaithersburg, MD</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Long-term agreement for Paragon to
support Novavax with product development and manufacturing</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>GAITHERSBURG,
MD, June 27, 2019</B> (GLOBE NEWSWIRE) &ndash; Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation
vaccines for serious infectious diseases, and Catalent Biologics&rsquo; Paragon Gene Therapy unit, the leading viral vector development
and manufacturing partner for gene therapies, today announced an arrangement under which Paragon Gene Therapy will assume the leases
to two Novavax product development and manufacturing facilities, giving it immediate access to state-of-the-art manufacturing equipment,
people and space to accelerate the growth of its gene therapy development and manufacturing business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">This
arrangement significantly reduces Novavax&rsquo; operating costs and provides a cash payment at closing of approximately $18 million.
This cost savings and cash infusion allow Novavax to focus on advancing NanoFlu&trade; and ResVax&trade; through the next phases
of clinical development and regulatory review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Under
the terms of the agreement, Paragon Gene Therapy will purchase from Novavax all of the related manufacturing equipment and facility
assets; in addition, over 100 of Novavax&rsquo; highly qualified manufacturing and quality employees will transfer to Paragon.
Concurrently, Novavax will be entering into a long-term arrangement with Paragon to provide process development and manufacturing
services for specified Novavax programs. The transactions are expected to close in July 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&ldquo;This
alliance is a true win-win-win for Paragon, Novavax and our employees,&rdquo; said Stanley C. Erck, President and Chief Executive
Officer of Novavax. &ldquo;This mutually beneficial transaction allows Paragon to quickly support the growth of its gene therapy
development and manufacturing business and simultaneously offers Novavax a strategic and cost-effective approach to addressing
its manufacturing needs into the future.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Most
Novavax employees at the two sites will transfer to Paragon and will continue to provide process and analytical development and,
potentially, manufacture GMP materials for Novavax&rsquo; clinical trial supplies for NanoFlu and ResVax, among other new projects.
These employees will also provide continuity and support of Novavax&rsquo; biologics license applications and post-licensure activities.
Over the longer term, Paragon will be available to manufacture commercial quantities of the vaccines for Novavax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&ldquo;Novavax&rsquo;
advanced GMP development and manufacturing capabilities and, even more importantly, its very strong team of experts, will help
accelerate our gene therapy manufacturing strategy and rapid growth,&rdquo; said Pete Buzy, President of Paragon&rsquo;s gene therapy
business. &ldquo;We welcome the new Novavax employees to the Paragon family and look forward to working closely together in this
strategic collaboration to advance Novavax&rsquo; innovative recombinant vaccines platform and expand our ability to serve the
burgeoning gene and cell therapy market.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&ldquo;This
transaction allows Novavax to focus on discovery, clinical work, regulatory licensure and commercialization of innovative vaccines
that may improve on existing approaches to prevent serious infectious diseases. We are happy to have found a great home for our
valued team members transferring to Paragon where they can make a real difference in developing new gene therapies and we thank
them for their important contributions to Novavax&rsquo; progress&rdquo; Mr. Erck said.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Novavax</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Novavax, Inc.
(Nasdaq:NVAX), is a late-stage biotechnology company that drives improved health globally through the discovery, development, and
commercialization of innovative vaccines to prevent serious infectious diseases. ResVax&trade;, its RSV vaccine for infants via
maternal immunization, is the only vaccine in a Phase 3 clinical program and is designed to prevent severe lower respiratory tract
infection which is the second leading cause of death in children under one year of age worldwide. Novavax is also advancing NanoFlu&trade;,
its quadrivalent influenza nanoparticle vaccine, to address key factors that can lead to the poor effectiveness of currently approved
flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines
the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent
global health needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information, visit <FONT STYLE="color: Blue"><U>www.novavax.com</U></FONT>
and connect with us on <FONT STYLE="color: Blue"><U>Twitter</U></FONT> and <FONT STYLE="color: Blue"><U>LinkedIn</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Catalent Biologics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Catalent
Biologics has 20+ years&rsquo; experience in development, manufacturing, and analytical services for new biological entities, biosimilars,
gene therapies and antibody-drug conjugates. Catalent has worked with 600+ mAbs and 80+ proteins, and more than 115 clinical trials
and 11 marketed products have used GPEx&reg; cell line engineering technology. A further 20 commercially-approved products have
employed Catalent Biologics&rsquo; capabilities through to aseptic fill/finish. Using advanced protein improvement technology and
tailored solutions from DNA through to clinical and commercial supply, Catalent Biologics brings better biologic treatments to
patients, faster. For more information, visit biologics.catalent.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Paragon
Gene Therapy, a unit of Catalent Biologics, is an industry leader focusing on transformative technologies, including gene therapies
(AAV), next-generation vaccines, and oncology immunotherapies. Paragon Gene Therapy has two facilities in Baltimore, Maryland dedicated
to process development through commercial manufacturing of most scalable AAV platforms across multiple serotypes. Since 2016, Paragon
Gene Therapy has completed over 100 clinical GMP AAV batches across 40 programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Statements herein
relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements.
Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual
results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified
under the heading &ldquo;Risk Factors&rdquo; in the Novavax Annual Report on Form 10-K for the year ended December 31, 2018, and
Quarterly Report on Form 10-Q for the period ended March 31, 2019, as filed with the Securities and Exchange Commission (SEC).
We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You
are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties.
The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation
to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contacts: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Investors</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Novavax, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Erika Trahan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Senior Manager, Investor &amp; Public Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Blue"><U>ir@novavax.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">240-268-2000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Westwicke Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Woolford</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Blue"><U>john.woolford@westwicke.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">443-213-0506</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Media</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">BrandZone/ KOGS Communication</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Edna Kaplan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Blue"><U>kaplan@kogspr.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">781-639-1910</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Catalent</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chris Halling</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+44 (0)7580 041073</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Blue"><U>chris.halling@catalent.com</U></FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I 0@# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#EO^$AUO\
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M;5CR[X8^(_[!\4I;S/ML[_$,F3PK_P #?F<?C7NFN:5%KFB7FF3XV7$13/\
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4'_Z$**TQ.'7/=:7(P]=\EGT/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
